Agile Therapeutics (NASDAQ:AGRX) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a note issued to investors on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Agile Therapeutics in a research report on Monday, March 18th.

Agile Therapeutics Stock Performance

Shares of NASDAQ AGRX opened at $0.42 on Friday. Agile Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $9.13. The stock has a market cap of $2.88 million, a price-to-earnings ratio of -0.04 and a beta of 1.42. The firm’s 50-day simple moving average is $0.76 and its 200 day simple moving average is $1.52.

Hedge Funds Weigh In On Agile Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in Agile Therapeutics in the 4th quarter valued at about $32,000. State Street Corp purchased a new stake in Agile Therapeutics in the 2nd quarter valued at about $32,000. Vanguard Group Inc. purchased a new stake in Agile Therapeutics in the 4th quarter valued at about $40,000. BlackRock Inc. increased its stake in Agile Therapeutics by 538.6% in the 3rd quarter. BlackRock Inc. now owns 303,799 shares of the specialty pharmaceutical company’s stock valued at $91,000 after buying an additional 256,227 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in Agile Therapeutics in the 2nd quarter valued at about $108,000. Institutional investors own 10.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.